利巴韦林
医学
肝细胞癌
纳米医学
间隙
丙型肝炎病毒
聚乙二醇干扰素
肝硬化
丙型肝炎
病毒学
干扰素
药物输送
病毒
免疫学
内科学
纳米技术
材料科学
纳米颗粒
泌尿科
作者
Noura H. Abd Ellah,Hesham M. Tawfeek,James John,Helal F. Hetta
出处
期刊:Nanomedicine
[Future Medicine]
日期:2019-06-01
卷期号:14 (11): 1471-1491
被引量:46
标识
DOI:10.2217/nnm-2018-0348
摘要
Hepatitis C virus (HCV) is not easily cleared from the human body and in most cases turned into chronic infection. This chronicity is a major cause of liver damage, cirrhosis and hepatocellular carcinoma. Therefore, immediate detection and treatment of HCV guarantees eradication of the virus and prevention of chronicity complications. Since discovery of HCV in 1989, several emerging treatments were developed such as polyethylene glycol(PEG)-ylated interferon/ribavirin, direct acting antivirals and host targeting antivirals. Despite the progress in anti-HCV therapy, there is still a pressing need of new approaches for affordable and effective drug delivery systems using nanomedicine. In this review, the contribution of nanoparticles as a promising delivery system for HCV immunizing, diagnostic and therapeutic agents are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI